Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Corline Biomedical

17.55 SEK

-1.13 %

Less than 1K followers

CLBIO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.13 %
-9.77 %
+17.00 %
+80.93 %
+99.89 %
+137.80 %
+84.35 %
+25.33 %
+77.42 %

Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.

Read more
Market cap
449.52M SEK
Turnover
7.38K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.2.
2026

Annual report '25

8.5.
2026

Interim report Q1'26

26.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Press release11/19/2025, 7:25 AM

Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming

Corline Biomedical
Press release9/2/2025, 8:29 AM

Redeye: Corline Biomedical - Kardium receives FDA approval

Corline Biomedical
Press release8/27/2025, 9:54 AM

Redeye: Corline Biomedical Q2 - Kardium’s Globe system nearing launch

Corline Biomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release5/11/2025, 3:51 PM

Redeye: Corline Biomedical Q1 - Exciting quarters ahead

Corline Biomedical
Press release2/18/2025, 7:34 AM

Redeye: Corline Biomedical Q4 - Focus on Kardium’s market launch

Corline Biomedical
Press release2/4/2025, 6:47 AM

Redeye: Redeye Initiates Coverage of Corline Biomedical

Corline Biomedical
Regulatory press release5/16/2019, 4:09 PM

Corline Biomedical AB: Will present at investor event hosted by Aktiespararna on June 3rd in Stockholm

Corline Biomedical
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.